Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy.

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Provided is a method for producing a CD4/CD8 double positive cell, including the following steps: step 1: separating, from a cell population containing a hematopoietic progenitor cell, a cell expressing one or more kinds of molecules selected from the first group consisting of CD24, CD62L, CD90, CD143, CD263, Notch3, CD32, CD39, CD49a, CD164, CD317, CD200, CD218a, CD7, CD144, CD56, CD226, CD262 and CD325, and/or a cell not expressing one or more kinds of molecules selected from the second group consisting of CD49f, CD51, CD102, CD42b, CD61, CD62P, CD69, CD102 and CD156c, and step 2: differentiating the cell separated in step 1 into a CD4/CD8 double positive cell.

Provided herein are populations of ex vivo expanded umbilical cord blood-derived regulatory T cells. Also provided are methods of making and using the same.

Aspects of the present disclosure relate to methods for manufacturing genetically engineered T cells expressing a chimeric antigen receptor (CAR) that provide several improvements over conventional manufacturing methods, thereby enabling production of a robust supply of clinically useful CAR T-cell therapies.

The present disclosure provides methods for improving the preparation efficiency of genetically modified immune cells and improving the quality of immune cells.

The present invention provides methods of preventing, reversing or increasing T cell exhaustion in a patient having a disease. The present invention also provides methods for treating a disease in a patient having the disease. The present invention also provides an engineered T cell comprising a high priority epigenetic pathway that has been targeted, and uses thereof.

A method of generating an enriched population of T cells for use in adoptive immunotherapy applications includes isolating T-cells from a biological sample of a subject, and separating a population of CD4/CD8 T cells having a CD45RA.sup.intCD45RO.sup.int phenotype from the isolated T cells.

A method for in vitro activation and/or expansion of immune cells is provided, including the steps of: a) providing magnetic particles having multi-protrusive surface modified with at least one type of immuno-inducing substance, in which each magnetic particle includes a copolymer core, a polymer layer, a magnetic substance layer, and a silicon-based layer from the inside to the outside; b) providing a cell solution including at least one type of immune cell in the cell solution; and c) bringing the magnetic particles in contact with the cell solution, in which the at least one type of immuno-inducing substance on the surface of the magnetic particle activates and/or expands the at least one type of immune cell in the cell solution.

The present disclosure relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include purifying peripheral blood mononuclear cells (PBMC) from a source, stimulating the PBMC with at least one HIV-specific peptide, depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8+ T cells, CD4+ T cells, cells, NK cells, B cells, T regulatory cells, and NKT cells, transducing the depleted PBMC with a viral delivery system encoding at least one genetic element, culturing the transduced PBMC for at least one day, and harvesting the cultured PBMC.